Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Voorhees, Timothy J., Zhao, Beibo, Oldan, Jorge, Hucks, George, Khandani, Amir, Dittus, Christopher, Smith, Jennifer, Morrison, J. Kaitlin, Cheng, Catherine J., Ivanova, Anastasia, Park, Steven, Shea, Thomas C., Beaven, Anne W., Dotti, Gianpietro, Serody, Jonathan, Savoldo, Barbara, Grover, Natalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864661/
https://www.ncbi.nlm.nih.gov/pubmed/34666347
http://dx.doi.org/10.1182/bloodadvances.2021005385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864661/
https://www.ncbi.nlm.nih.gov/pubmed/34666347
http://dx.doi.org/10.1182/bloodadvances.2021005385

Ejemplares similares